Consequently, we are cautiously optimistic that TRAF1-mediated activation of the ASK1 pro-death signalling pathway is a promising therapeutic target for stroke management, likely beyond the accessible window of opportunity for tPA therapy. Here, MAP3K5 is linked to stroke disorder.